Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: "Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy. | Radiation Oncology BioMed Central Research Open Access Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy Matthew Beasley1 Scott G Williams2 5 Tom Pickles 1 and The BCCA Prostate Outcomes Unit1 Address 1British Columbia Cancer Agency Vancouver Canada and 2Peter MacCallum Cancer Centre Melbourne Australia Email Matthew Beasley - mbeasley@doctors.org.uk Scott G Williams - Scott.Williams@petermac.org Tom Pickles - tpickles@bccancer.bc.ca The BCCA Prostate Outcomes Unit - PCOI@bccancer.bc.ca Corresponding author Published 18 April 2008 Received 9 October 2007 Radiation Oncology 2008 3 8 doi 10.1186 1748-717X-3-8 Accepted 18 April 2008 This article is available from http www.ro-journal.cOm content 3 1 8 2008 Beasley et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Purpose To assess whether an expanded five level risk stratification system can be used to identify the sub-group of intermediate risk patients with prostate cancer who benefit from combining androgen deprivation therapy ADT with external beam radiotherapy EBRT . Materials and methods Using a previously validated 5-risk group schema a prospective nonrandomized data set of 1423 men treated at the British Columbia Cancer Agency was assessed for the primary end point of biochemical control bNED with the RTOG-ASTRO Phoenix definition lowest PSA to date 2 ng mL both with and without adjuvant ADT. The median follow-up was 5 years. Results There was no bNED benefit for ADT in the low or low intermediate groups but there was a statistically significant bNED benefit in the high intermediate high and extreme risk groups. The 5-year bNED rates with and without ADT were 70 and 73 .
